The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link BPC 157: Experimental Peptide Creates Risk for Athletes FDA Vs. California Law: Where Peptide Compliance Actually Breaks Down Holt Law